Early data from the ADAPT JR trial suggest efgartigimod may benefit adolescents with generalized myasthenia gravis, a rare ...

PHM continues to advance with diverse research impacting clinical care, quality improvement, and health equity. The top 10 ...

An updated guide to timing, parts, costs and coordination so you don’t get stuck with penalties or surprises at 65.

Learn more about whether ADMA Biologics, Inc. or Arcus Biosciences, Inc. is a better investment based on AAII's A+ Investor ...

First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session ...

The introduction of five upcoming registrational readouts for 2026 is a new forward-looking highlight. Product net sales and operating profit both increased meaningfully quarter-over-quarter, as did ...

A study showed babies who have ABO-mediated HDFN should be checked for signs of jaundice two to three times during the first ...

Despite advances in screening and treatment, HDFN remains a significant cause of perinatal morbidity and mortality worldwide.